Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | TTR | P02766 | 1/20 | 0.45 |
| ▸ | FDPS | P14324 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 4/20 | 0.40 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.40 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.40 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.40 |
| ▸ | ABAT | P80404 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 2/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4637716 | 0.74 | ALDH1A1 (0.55) | ALDH1A1TSHRTTRFDPSHPGD | |
| SCHEMBL7278320 | 0.73 | PDE4B (0.60) | ALDH1A1TSHRPDE4APDE4BPDE4C | |
| SCHEMBL7270844 | 0.73 | PDE4B (0.60) | ALDH1A1TSHRPDE4APDE4BPDE4C | |
| SCHEMBL7278324 | 0.73 | PDE4B (0.60) | ALDH1A1TSHRPDE4APDE4BPDE4C | |
| SCHEMBL6582284 | 0.73 | ALDH1A1 (0.54) | ALDH1A1TSHRTTRFDPSMAPT | |
| SCHEMBL7288403 | 0.73 | PDE4B (0.60) | ALDH1A1TSHRPDE4APDE4BPDE4C | |
| SCHEMBL4637207 | 0.73 | PDE4B (0.60) | ALDH1A1TSHRPDE4APDE4BPDE4C | |
| SCHEMBL7355695 | 0.73 | PDE4B (0.40) | ALDH1A1MAPTLMNAPDE4APDE4B | |
| SCHEMBL4637148 | 0.73 | PDE4A (0.43) | SMN1; SMN2LMNAPDE4APDE4BPDE4C | |
| SCHEMBL6863216 | 0.73 | ALDH1A1 (0.57) | ALDH1A1TSHRTTRFDPSMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1468991-B1 | Imides as PDE III, PDE IV and TNF inhibitors | CELGENE CORP (US) | 2008-02-20 | — | — | EP | disclosed |
| US-7081464-B2 | Topical compositions of cyclic amides as immunotherapeutic agents | CELGENE CORPORATION (US) | 2006-07-25 | — | — | US | disclosed |
| US-20060003979-A1 | Topical compositions of cyclic amides as immunotherapeutic agents | CELGENE CORPORATION | 2006-01-05 | — | — | US | disclosed |
| EP-1468991-A1 | Imides as PDE III, PDE IV and TNF inhibitors | CELGENE CORPORATION (US) | 2004-10-20 | — | — | EP | disclosed |
| EP-0874819-B1 | IMIDES AS PDE III, PDE IV AND TNF INHIBITORS | CELGENE CORP (US) | 2004-05-26 | — | — | EP | disclosed |
| US-6518281-B2 | Heterocyclic amides/imides as inhibitors of tumor necrosis factor alpha and nuclear factor kappa B and phosphodi-esterases III and IV; used to combat cachexia, endotoxic shock, retrovirus replication and asthma; antiinflammatory | CELGENE CORPORATION | 2003-02-11 | — | — | US | disclosed |
| EP-0874819-A1 | IMIDES AS PDE III, PDE IV AND TNF INHIBITORS | CELGENE CORPORATION (US) | 1998-11-04 | — | — | EP | disclosed |
| WO-1997023457-A1 | IMIDES AS PDE III, PDE IV AND TNF INHIBITORS | CELGENE CORPORATION (US) | 1997-07-03 | — | — | WO | disclosed |
| US-5459145-A | Calcium independent camp phosphodiesterase inhibitor antidepressant | PFIZER INC. (US) | 1995-10-17 | — | — | US | disclosed |
| US-5294730-A | A-Amino-4-alkoxy-3-polycycloalkyloxybenzyl cyanide derivatives | PFIZER INC. (US) | 1994-03-15 | — | — | US | disclosed |
| EP-0247725-B1 | Calcium independent camp phosphodiestrerase inhibitor antidepressant | PFIZER (US) | 1994-03-02 | — | — | EP | disclosed |
| US-5196426-A | CALCIUM INDEPENDENT C AMP PHOSPHODIESTERASE INHIBITOR ANTIDEPRESSANT | PFIZER INC. (US) | 1993-03-23 | — | — | US | disclosed |
| US-5128358-A | Aryl substituted nitrogen heterocyclic antidepressants | PFIZER INC. (US) | 1992-07-07 | — | — | US | disclosed |
| EP-0247725-A2 | Calcium independent camp phosphodiestrerase inhibitor antidepressant | PFIZER INC. (US) | 1987-12-02 | — | — | EP | disclosed |
| WO-1987006576-A1 | CALCIUM INDEPENDENT CAMP PHOSPHODIESTERASE INHIBITOR ANTIDEPRESSANT | PFIZER INC. (US) | 1987-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060003979-A1 | Topical compositions of cyclic amides as immunotherapeutic agents | TSLP, STING1, CGAS | ALDH1A1 3455/4885TSHR 3945/4885TTR 4261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.